Early Identification of HERG Liability in Drug Discovery Programs by Automated Patch Clamp

Overview

Journal Front Pharmacol

Date 2014 Sep 18

PMID 25228880

Citations 36

Authors

Timm Danker

Clemens Moller

Affiliations

Soon will be listed here.

Abstract

Blockade of the cardiac ion channel coded by human ether-à-gogo-related gene (hERG) can lead to cardiac arrhythmia, which has become a major concern in drug discovery and development. Automated electrophysiological patch clamp allows assessment of hERG channel effects early in drug development to aid medicinal chemistry programs and has become routine in pharmaceutical companies. However, a number of potential sources of errors in setting up hERG channel assays by automated patch clamp can lead to misinterpretation of data or false effects being reported. This article describes protocols for automated electrophysiology screening of compound effects on the hERG channel current. Protocol details and the translation of criteria known from manual patch clamp experiments to automated patch clamp experiments to achieve good quality data are emphasized. Typical pitfalls and artifacts that may lead to misinterpretation of data are discussed. While this article focuses on hERG channel recordings using the QPatch (Sophion A/S, Copenhagen, Denmark) technology, many of the assay and protocol details given in this article can be transferred for setting up different ion channel assays by automated patch clamp and are similar on other planar patch clamp platforms.

Citing Articles

In Vitro and In Silico Evaluation of Essential Oil: Effects on Mitochondrial Function and Cytotoxic Potential Against Cancer Cells.

Munteanu A, Gogulescu A, Soica C, Mioc A, Mioc M, Milan A Plants (Basel). 2024; 13(23).

PMID: 39683236 PMC: 11644429. DOI: 10.3390/plants13233443.

hERG channel agonist NS1643 strongly inhibits invasive astrocytoma cell line SMA-560.

Benn K, Yuan P, Chong H, Stylii S, Luwor R, French C PLoS One. 2024; 19(9):e0309438.

PMID: 39240809 PMC: 11379238. DOI: 10.1371/journal.pone.0309438.

Lead optimisation of OXS007417: PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.

Cogswell T, Josa-Cullere L, Zimmer D, Galan S, Jay-Smith M, Harris K RSC Med Chem. 2024; .

PMID: 39220761 PMC: 11361297. DOI: 10.1039/d4md00275j.

2,8-Disubstituted-1,5-naphthyridines as Dual Inhibitors of Phosphatidylinositol-4-kinase and Hemozoin Formation with Efficacy.

Dziwornu G, Seanego D, Fienberg S, Clements M, Ferreira J, Sypu V J Med Chem. 2024; 67(13):11401-11420.

PMID: 38918002 PMC: 11247499. DOI: 10.1021/acs.jmedchem.4c01154.

Assembly of Cell-Free Synthesized Ion Channel Molecules in Artificial Lipid Bilayer Observed by Atomic Force Microscopy.

Goh M, Tozawa Y, Tero R Membranes (Basel). 2023; 13(11).

PMID: 37999340 PMC: 10673230. DOI: 10.3390/membranes13110854.

References

Finkel A, Wittel A, Yang N, Handran S, Hughes J, Costantin J . Population patch clamp improves data consistency and success rates in the measurement of ionic currents. J Biomol Screen. 2006; 11(5):488-96. DOI: 10.1177/1087057106288050. View

Milligan C, Li J, Sukumar P, Majeed Y, Dallas M, English A . Robotic multiwell planar patch-clamp for native and primary mammalian cells. Nat Protoc. 2009; 4(2):244-55. PMC: 2645065. DOI: 10.1038/nprot.2008.230. View

Wisniowska B, Polak S . hERG in vitro interchange factors--development and verification. Toxicol Mech Methods. 2009; 19(4):278-84. DOI: 10.1080/15376510902777194. View

Gintant G, Gallacher D, Pugsley M . The 'overly-sensitive' heart: sodium channel block and QRS interval prolongation. Br J Pharmacol. 2011; 164(2):254-9. PMC: 3174406. DOI: 10.1111/j.1476-5381.2011.01433.x. View

Fenichel R, Malik M, Antzelevitch C, Sanguinetti M, Roden D, Priori S . Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol. 2004; 15(4):475-95. PMC: 1544371. DOI: 10.1046/j.1540-8167.2004.03534.x. View

Polonchuk L . Toward a New Gold Standard for Early Safety: Automated Temperature-Controlled hERG Test on the PatchLiner. Front Pharmacol. 2012; 3:3. PMC: 3266667. DOI: 10.3389/fphar.2012.00003. View

Davenport A, Moller C, Heifetz A, Mazanetz M, Law R, Ebneth A . Using electrophysiology and in silico three-dimensional modeling to reduce human Ether-à-go-go related gene K(+) channel inhibition in a histamine H3 receptor antagonist program. Assay Drug Dev Technol. 2010; 8(6):781-9. DOI: 10.1089/adt.2010.0322. View

Becknell N, Dandu R, Lyons J, Aimone L, Raddatz R, Hudkins R . Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists. Bioorg Med Chem Lett. 2011; 22(1):186-9. DOI: 10.1016/j.bmcl.2011.11.038. View

Kirsch G, Trepakova E, Brimecombe J, Sidach S, Erickson H, Kochan M . Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods. 2004; 50(2):93-101. DOI: 10.1016/j.vascn.2004.06.003. View

10.

Roden D, LAZZARA R, Rosen M, Schwartz P, Towbin J, Vincent G . Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation. 1996; 94(8):1996-2012. DOI: 10.1161/01.cir.94.8.1996. View

11.

Dunlop J, Bowlby M, Peri R, Vasilyev D, Arias R . High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nat Rev Drug Discov. 2008; 7(4):358-68. DOI: 10.1038/nrd2552. View

12.

Curran M, Splawski I, Timothy K, Vincent G, Green E, Keating M . A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995; 80(5):795-803. DOI: 10.1016/0092-8674(95)90358-5. View

13.

Golden A, Li N, Chen Q, Lee T, Nevill T, Cao X . IonFlux: a microfluidic patch clamp system evaluated with human Ether-à-go-go related gene channel physiology and pharmacology. Assay Drug Dev Technol. 2011; 9(6):608-19. DOI: 10.1089/adt.2010.0362. View

14.

Haythornthwaite A, Stoelzle S, Hasler A, Kiss A, Mosbacher J, George M . Characterizing human ion channels in induced pluripotent stem cell-derived neurons. J Biomol Screen. 2012; 17(9):1264-72. DOI: 10.1177/1087057112457821. View

15.

Gintant G, Hoffman B . Use-dependent block of cardiac sodium channels by quaternary derivatives of lidocaine. Pflugers Arch. 1984; 400(2):121-9. DOI: 10.1007/BF00585029. View

16.

Stoelzle S, Haythornthwaite A, Kettenhofen R, Kolossov E, Bohlen H, George M . Automated patch clamp on mESC-derived cardiomyocytes for cardiotoxicity prediction. J Biomol Screen. 2011; 16(8):910-6. DOI: 10.1177/1087057111413924. View

17.

Anderson J, Campbell M, Wang J, Brunden K, Harrington J, Stricker-Krongrad A . Investigation of 4-piperidinols as novel H3 antagonists. Bioorg Med Chem Lett. 2010; 20(21):6246-9. DOI: 10.1016/j.bmcl.2010.08.099. View

18.

Park S, Kim K, Kim E . Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656. J Appl Toxicol. 2007; 28(2):104-11. DOI: 10.1002/jat.1252. View

19.

Becker N, Stoelzle S, Gopel S, Guinot D, Mumm P, Haarmann C . Minimized cell usage for stem cell-derived and primary cells on an automated patch clamp system. J Pharmacol Toxicol Methods. 2013; 68(1):82-7. DOI: 10.1016/j.vascn.2013.03.009. View

20.

De Bruin M, Pettersson M, Meyboom R, Hoes A, Leufkens H . Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J. 2005; 26(6):590-7. DOI: 10.1093/eurheartj/ehi092. View